drugset / Trial / NCT04187625

Cell-based Therapy for the Treatment of Kidney Disease

NCT04187625 ↗

Phase 0 Unknown 10 enrolled Brigham and Women's Hospital
NaSingle-groupOpen-labelTreatment

Summary

Endothelial progenitor cells derived from and delivered to the renal vasculature may be stimulated to initiate differentiation programs during episodes of injury. It is hypothesized that endothelial progenitor cells from the kidney can transition to a phenotype that promotes endothelial repair.

Timeline

Start
2023-01-01
Primary completion
2024-01-01
Completion
2025-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject endothelial progenitor cell Cell therapy — Other

Indications